Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Postmarket Drug Safety Pilot Will Consider Between Five And 10 Drugs

Executive Summary

FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities

You may also be interested in...



FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact

FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain

FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact

FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain

Two Postmarket NME Safety Reviews Done; Five To Be Finished By Early ’08

FDA has completed safety reviews for two new molecular entities as part of a pilot program to determine whether preparing postmarket safety profiles would enhance the existing system for monitoring adverse events

Related Content

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel